dupilumab biosimilar / Daewoong Pharma - LARVOL DELTA

Chime Biologics And Daewoong Pharmaceutical Partner To Advance Global Dupilumab Biosimilar Development (BioPharma APAC) - "Chime Biologics will leverage its extensive end-to-end biosimilar development and commercialization experience, advanced AI-enabled development platform(Chime AI Platform) and bioprocess supply chain ecosystem(Chime Innovation Alliance) to support Daewoong Pharmaceutical's global biosimilar ambitions. The partnership reflects both companies' commitment to delivering high-quality and accessible biologic medicines to patients worldwide."

Licensing / partnership • Asthma • Atopic Dermatitis • Bullous Pemphigoid • Chronic Obstructive Pulmonary Disease • Chronic Rhinosinusitis With Nasal Polyps • Chronic Spontaneous Urticaria • Eosinophilic Esophagitis • Immunology • Prurigo Nodularis